



# IVCC

COMBATING INSECT  
BORNE DISEASE

The Innovative Vector  
Control Consortium

# Barriers to Innovation in the development of Public Health

Dr Robert Sloss IVCC

15/05/09

# Barriers to Innovation in the development of new Public health Products

- The cost of development related to market size
  - The cost of developing a totally new insecticide active ingredient for Public Health is estimated at \$ 100 – 150 Million against a market size for insecticides alone of \$ 400 Million
  - The cost of developing a new product from an existing insecticide is estimated at \$ 4-6 Million
- Time to development, for a new active ingredient this is 10-12 years, for a new product 4-6 years
- Market Place uncertainties
  - Funding for vector control within countries is variable and difficult to predict
  - Market intelligence is limited and difficult to obtain
- Limited number of suitable available insecticide active ingredients not already recommended by WHOPES
- There are a limited number of suitable field trial testing sites
- Internal company resources.
  - Competition inside large companies for key resources such as regulatory affairs, project managers and development resource
  - Smaller companies are unable to justify full time resource in key areas

15/05/09



**IVCC**  
COMBATING INSECT  
BORNE DISEASE  
The Innovative Vector  
Control Consortium

# Regulatory Barriers to Innovation in the development of new Public health Products

- Regulatory Uncertainties
  - Local country regulatory timelines and costs uncertain
  - Small company understanding of the regulatory process
  - Poorly defined regulatory efficacy standards
- Large number of countries with different processes, costs and timelines
- Long overall regulatory process for products
- Lack of independent GLP audited laboratories and trial sites for efficacy testing
- No process for approving innovative approaches to vector control

15/05/09



**IVCC**  
COMBATING INSECT  
BORNE DISEASE  
The Innovative Vector  
Control Consortium

# Overcoming Barriers to innovation

The reduction of supply side barriers including:-

- Financial risk reduction by contributions to the developers to reduce their development costs.
- Confidence Building
  - ESAC recommendation
  - Market knowledge.
- Insecticide testing capabilities
- Provision of enabling resources
  - registration expertise,
  - key technology brokering and
  - project managers.

15/05/09



**IVCC**  
COMBATING INSECT  
BORNE DISEASE  
The Innovative Vector  
Control Consortium

# Overcoming Regulatory barriers to innovation in the development of new Public Health products

- Product quality delivered by Global performance standards for each product class
- Safety delivered by a risk based regulatory process
  - Transparent and Published
  - Standardised evaluation
- All testing carried out by independent GLP audited laboratories and field trial sites
- Clearly defined published and publicised overall regulatory process
- A defined process for setting new performance standards for new classes of products and reviewing and changing standards for current product classes.

15/05/09



**IVCC**  
COMBATING INSECT  
BORNE DISEASE  
The Innovative Vector  
Control Consortium